A Randomized Double Blind Phase II Trial of Platinum Therapy plus Etoposide with/without Concurrent ZD6474 in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113.

Trial Profile

A Randomized Double Blind Phase II Trial of Platinum Therapy plus Etoposide with/without Concurrent ZD6474 in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Vandetanib (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Sep 2016 Results assessing addition of Vandetanib to platinum and etoposide on outcomes of the study published in the Cancer (2016).
    • 17 Nov 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top